Disease progression in patients with colon cancer can now be defined more accurately with Immunoscore, a test devised by a team of researchers from Inserm and Université Paris Descartes and doctors from the Paris AP-HP hospitals.
According to an international study conducted in more than 2,500 patients, Immunoscore has proved effective in predicting which patients are at high risk of tumour recurrence and, as such, would benefit from intensified treatment following surgery.
These results have been published in The Lancet.
The seriousness of cancer, and particularly that of the colon, is essentially estimated according to the extent to which it has spread within the affected organ and the presence of metastasis.
This estimation of the aggressiveness of the cancer and its risk of recurrence following treatment must however be improved.
For decades, it has been thought that the immune reaction developed by the patient against his or her cancer has a beneficial influence.
Researchers from Inserm and doctors from the Paris AP-HP hospitals have demonstrated in recent years that infiltration of the cancerous tumour by immune cells is a good indication of the way in which colorectal cancer might develop, thereby representing a potential prognostic tool.
The immune cell populations which provide the most information on disease progression were identified and the method of evaluating these populations optimized.
This method has led to the creation of an immunological test, applicable in clinical practice, called "Immunoscore".
It works by quantifying the density of two types of immune cells in the tumour and its invasive margin: total T-cells (CD3 ) and killer T-cells (cytotoxic CD8 ).
The objective of this international study published in The Lancet was to evaluate the prognostic value of Immunoscore in patients with colon cancer on a very large scale.
For this, an international consortium of 14 immunology and pathology centers in 13 countries was formed.
A total of 2,681 patients from these centers were included in this analysis.
The prognostic performance of Immunoscore, in which patients are classified into 3 groups (high, intermediate and low), was evaluated on the basis of recurrence risk (evaluated during the 5 years following the surgery) and survival.
The statistical analyses were all performed by a group of external biostatisticians from the Mayo Clinic in the USA.
The results show that patients with a high Immunoscore present the lowest recurrence risk and prolonged survival.
In the test group comprising 700 patients, only 8% of those with a high Immunoscore presented a recurrence after 5 years.
However, the recurrence rate increased significantly in patients with intermediate and low Immunoscores, reaching 19% and 32%, respectively.
These findings were confirmed in the two other patient groups analyzed, representing 1,981 patients.
Furthermore, Immunoscore had a stronger bearing on patient survival than the tumour criteria which are currently used to guide therapy.
These findings show that Immunoscore provides an accurate and reliable estimation of recurrence risk in patients with colon cancer.
The researchers consider that these results support the use of Immunoscore as a new component in the classification of cancer, in which recurrence risk is used to improve individual patient treatment strategies, particularly the modulation of chemotherapy.
In view of the highly positive results of this test in colon cancer, researchers are currently evaluating Immunoscore in other types of cancer and are studying its ability to predict patient response to the immunotherapies which are currently revolutionizing the treatment of cancer.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.